Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study
Language English Country England, Great Britain Media print-electronic
Document type Comparative Study, Journal Article
- Keywords
- adalimumab, atherosclerosis, biomarkers, cardiovascular, psoriasis,
- MeSH
- Adalimumab administration & dosage adverse effects therapeutic use MeSH
- beta 2-Glycoprotein I blood MeSH
- Biomarkers blood MeSH
- C-Reactive Protein analysis MeSH
- Vascular Cell Adhesion Molecule-1 blood MeSH
- Dermatologic Agents administration & dosage adverse effects therapeutic use MeSH
- Adult MeSH
- E-Selectin blood MeSH
- Interleukin-22 MeSH
- Interleukins blood MeSH
- Cardiovascular Diseases blood complications MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipoproteins, LDL blood MeSH
- Pilot Projects MeSH
- Psoriasis blood complications drug therapy MeSH
- Risk Factors MeSH
- Tumor Necrosis Factor-alpha antagonists & inhibitors MeSH
- Healthy Volunteers MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Names of Substances
- Adalimumab MeSH
- beta 2-Glycoprotein I MeSH
- Biomarkers MeSH
- C-Reactive Protein MeSH
- Vascular Cell Adhesion Molecule-1 MeSH
- Dermatologic Agents MeSH
- E-Selectin MeSH
- Interleukins MeSH
- Lipoproteins, LDL MeSH
- oxidized low density lipoprotein MeSH Browser
- SELE protein, human MeSH Browser
- Tumor Necrosis Factor-alpha MeSH
Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-α, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: C-reactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/β-glycoprotein I complex (oxLDL/β2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-β2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-α seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.
References provided by Crossref.org
